1,124 results on '"Planchard, D."'
Search Results
352. 1416P - Immunosenescence (iSenescence) correlates with disease progression in advanced non-small cell lung cancer (aNSCLC) patients treated with PD-(L)1 inhibitors (IO)
353. 1408P - Prognostic factors in non-small cell lung cancer (NSCLC) patients (pts) with brain metastases (BM) treated with immune checkpoint inhibitors (ICI)
354. 1407P - Derived neutrophil-to lymphocyte ratio (dNLR) change between baseline and cycle 2 is correlated with benefit during immune checkpoint inhibitors (ICI) in advanced non-small cell lung cancer (NSCLC) patients
355. 1378O - ARCTIC: Durvalumab + tremelimumab and durvalumab monotherapy vs SoC in ≥ 3L advanced NSCLC treatment
356. 30P - Clinical validation and utility of InVision ctDNA in advanced non-small cell lung cancer (NSCLC) patients
357. 24P - Clinical outcomes in patients with advanced NSCLC treated with targeted therapies, with actionable mutations identified by InVisionFirst ctDNA assay
358. Caractérisation des tumeurs neuroendocrines digestives ou thoraciques
359. P2.22-03 NUT Midline Carcinoma (NC) Deciphering the Standard of Care in an Ultra-rare Cancer
360. EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients
361. 3081 Molecular Tumor Board (MTB) in non-small cell lung cancers (NSCLC) to optimize targeted therapies: 4 years' experience at Gustave Roussy
362. 3076 Tumor control of advanced pulmonary carcinoid tumors with somatostatin analogs: Experience at Gustave Roussy
363. 3025 Prognostic value of PDL1 expression in stage III Non-Small Cell Lung Cancer (NSCLC) treated by chemo-radiotherapy (CRT)
364. 3000 Chemo-radiation (CRT) and mutation profile in stage III Non Small Cell Lung Cancer (NSCLC): An analysis of the prognostic value
365. High level of chromosomal instability in circulating tumor cells of ROS1-rearranged non-small-cell lung cancer
366. A randomized phase II study of the MEK1/MEK2 inhibitor trametinib (GSK1120212) compared with docetaxel in KRAS-mutant advanced non-small-cell lung cancer (NSCLC)
367. Afatinib (A) Plus Paclitaxel (P) Following Progression on a Monotherapy in Patients (PTS) with Metastatic Non–Small-Cell Lung Cancer (NSCLC) Who Previously Benefited From Erlotinib (E)/Gefitinib (G): a Global Randomised Phase Iii Trial–Lux-Lung 5 (LL5)
368. Phase 2 Study of Nivolumab (ANTI-PROGRAMMED DEATH-1 [PD-1]) in Patients (PTS) with Advanced, Refractory Squamous (SQ) Non-Small Cell Lung Cancer (NSCLC)
369. A Phase I Study of AZD9291 in Patients with Egfr-Tki-Resistant Advanced Nsclc – Updated Progression Free Survival and Duration of Response Data
370. Post-first-line FOLFOX chemotherapy for grade 3 neuroendocrine carcinoma
371. AZD9291 a novel EGFR-TKI that overcomes T790M-mediated resistance in NSCLC
372. Continuation of afatinib (A) beyond progression: results of a randomized, open-label, phase III trial of A plus paclitaxel (P) versus investigator's choice chemotherapy (CT) in patients (pts) with metastatic non-small-cell lung cancer (NSCLC) progressed on erlotinib/gefitinib (E/G) and A: LUX-Lung 5 (LL5)
373. Phase II Study of Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in Patients with Advanced, Refractory Squamous Non-Small Cell Lung Cancer
374. 403O - PACIFIC: A double-blind, placebo-controlled Phase III study of durvalumab as consolidation therapy after chemoradiation in patients with locally advanced, unresectable NSCLC
375. E4 - Molecular profile characterization and impact on clinical outcome in metastatic NSCLC patients enrolled in MOSCATO 01 trial
376. LBA1_PR - PACIFIC: A double-blind, placebo-controlled phase III study of durvalumab after chemoradiation therapy (CRT) in patients with stage III, locally advanced, unresectable NSCLC
377. LBA51 - Phase 2 trial (BRF113928) of dabrafenib (D) plus trametinib (T) in patients (pts) with previously untreated BRAF V600E–mutant metastatic non-small cell lung cancer (NSCLC)
378. 1618PD - Overall survival (OS) and forced vital capacity (FVC) results from the LUME-Meso study of nintedanib (N) + pemetrexed/cisplatin (PEM/CIS) vs placebo (P) + PEM/CIS in chemo-naïve patients (pts) with malignant pleural mesothelioma (MPM)
379. 1386O - Cancer cachexia (CAX), anorexia and muscle wasting (sarcopenia) assessment in non-small cell lung cancer (NSCLC): an observational study in 531 patients
380. 1381TiP - A randomized double-blind phase II trial evaluating maintenance PARP inhibitor Olaparib versus placebo in patients with platinum-sensitive advanced non-small cell lung cancer: PIPSeN trial
381. 1327P - The Lung Immune Prognostic Index (LIPI), a predictive score for immune checkpoint inhibitors in advanced non-small cell lung cancer (NSCLC) patients
382. 1323P - Baseline corticosteroids (CS) could be associated with absence of benefit to immune checkpoint inhibitors (ICI) in advanced non-small cell lung cancer (NSCLC) patients
383. 1306PD - Hyperprogressive disease (HPD) is frequent in non-small cell lung cancer (NSCLC) patients (pts) treated with anti PD1/PD-L1 monoclonal antibodies (IO)
384. 1164P - Patterns of progression under antiPD1/PDL1 in advanced NSCLC patients allow discriminating pseudo-progression from real progression
385. 112P - Pathological evaluation of tumor infiltrating lymphocytes and the benefit of nivolumab in advanced non-small cell lung cancer (NSCLC)
386. EP08.02-060 How Do Oncologists Treat Patients With EGFR Exon-20 Mutant NSCLC Outside of Clinical Trials? Updated Analysis From the European EXOTIC Registry.
387. Phase II Study of Nivolumab (anti-PD-1, BMS-936558, ONO-4538) in Patients with Advanced, Refractory Squamous Non-Small Cell Lung Cancer
388. Phase I Study of Tremelimumab (Trem) in Combination with Gefitinib (Gef) in Epidermal Growth Factor Receptor Mutant (Egfr-Mut) Non-Small Cell Lung Cancer (Nsclc)
389. Patient-Reported Outcomes (Pros) in Patients (Pts) with Advanced Non-Small Cell Lung Cancer (Nsclc) Receiving Afatinib (A) Monotherapy Followed By a + Paclitaxel (A + P) Vs Investigator'S Choice of Single-Agent Chemotherapy (Ic): Lux-Lung 5 (Ll5)
390. Afatinib (A) Followed By a + Paclitaxel (P) or Investigator'S Choice of Single-Agent Chemotherapy (Ic) in Patients (Pts) with Advanced Squamous Cell Carcinoma (Scc) of the Lung: Subgroup Analysis of Lux-Lung 5 (Ll5)
391. Dabrafenib in Patients with Braf V600E-Mutant Advanced Non-Small Cell Lung Cancer (Nsclc): a Multicenter, Open-Label, Phase Ii Trial (Brf113928)
392. Preliminary Azd9291 Western and Asian Clinical Pharmacokinetics (Pk) in Patients (Pts) and Healthy Volunteers (Hv): Implications for Formulation, Dose and Dosing Frequency in Pivotal Clinical Studies
393. Levels of Egfr T790M in Plasma Dna As a Predictive Biomarker for Response to Azd9291, a Mutant-Selective Egfr Kinase Inhibitor
394. Updated Safety and Efficacy from a Phase I Study of Azd9291 in Patients (Pts) with Egfr-Tki-Resistant Non-Small Cell Lung Cancer (Nsclc)
395. Efficacy of phase 1 trials in malignant pleural mesothelioma: Description of a series of patients at a single institution
396. Malignant pleural mesothelioma
397. Does KRAS mutational status predict chemoresistance in advanced non-small cell lung cancer (NSCLC)?
398. 158P Real-world management of patients with EGFR exon 20-mutant NSCLC in the precision oncology era: First report from the European EXOTIC registry.
399. 1245P - Phase I, safety, tolerability and preliminary efficacy study of tremelimumab (Trem) in combination with gefitinib (Gef) in EGFR-mutant (EGFR-mut) NSCLC (GEFTREM)
400. 1260P - Safety of necitumumab and pembrolizumab combination therapy in patients with stage IV non-small cell lung cancer (NSCLC): a phase 1b expansion cohort study
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.